盐酸羟考酮缓释片联合硫酸吗啡缓释片治疗中晚期癌症患者爆发痛的效果

摘要
图/表
参考文献(22)
相关文章 (3)

全文: PDF (0 KB) HTML (39 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨盐酸羟考酮缓释片联合硫酸吗啡缓释片治疗中晚期癌症患者爆发痛的效果。方法选取2015年12月至2018年12月济宁北湖省级旅游度假区人民医院的104 例癌痛患者作为研究对象，采用随机抽签法将其分为对照组（52 例）和观察组（52 例），对照组采用口服硫酸吗啡缓释片法，观察组采用口服硫酸吗啡缓释片联合盐酸羟考酮缓释片法。比较两组患者治疗后疼痛缓解率、血清指标、疼痛稳定时间、爆发痛次数，治疗前后生活质量评分及不良反应发生情况。结果治疗后，两组的疼痛缓解率比较，差异无统计学意义（P＞0.05）。观察组患者治疗后的血清肿瘤坏死因子-α（TNF-α）、白细胞介素-6（IL-6）、P 物质（SP）低于治疗前，5-羟色胺（5-HT）、β-内啡肽（β-EP）高于治疗前，差异有统计学意义（P＜0.05）；观察组治疗后的血清TNF-α、IL-6、SP 低于对照组，5-HT、β-EP 高于对照组，差异有统计学意义（P＜0.05）。观察组爆发痛次数少于对照组、疼痛稳定时间短于对照组，差异有统计学意义（P＜0.05）。观察组治疗后的生活质量评分高于对照组，差异有统计学意义（P＜0.05）。两组患者的不良反应总发生率比较，差异无统计学意义（P＞0.05）。结论盐酸羟考酮缓释片联合硫酸吗啡缓释片可有效降低癌痛患者爆发痛次数，并进一步提升疼痛缓解率，缩短疼痛稳定时间，改善患者生活质量。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	姚辉杰

关键词 ：癌性疼痛, 盐酸羟考酮缓释片, 硫酸吗啡缓释片, 爆发痛, 疼痛稳定时间

Abstract：Objective To investigate the effect of Hydroxycodone Hydrochloride Sustained-release Tablets combined with Morphine Sulfate Sustained-release Tablets on pain outbreak in patients with advanced cancer. Methods A total of 104 patients with cancer pain in the People′s Hospital of Jining Beihu Provincial Tourism Resort from December 2015 to December 2018 were selected and use random lotteny to divided into control group(52 cases)and observation group(52 cases). The control group was treated with oral morphine sulfate sustained-release tablets, and the observation group was treated with oral Morphine Sulfate Sustained-release Tablets combined with Hydroxycodone hydrochloride Sustainedrelease Tablets. The pain relief rate, serum index, pain stability time, number of outbreaks of pain, quality of life score and incidence of adverse reactions were compared between the two groups after treatment. Results After treatment,there was no statistically significant difference in the pain relief rate between the two groups(P＞0.05).Serum tumor necrosis facctor-α (TNF-α), interleukin-6 (IL-6), substance P (SP) of observation group after treatment were lower than before treatment, 5-hydroxytryptamine (5-HT) and β-endorphin (β-EP) were higher than before treatment, the differences were statistically significant (P＜0.05); serum of observation group after treatment TNF-α, IL-6, SP were lower than the control group, 5-HT, β-EP were higher than the control group, the differences were statistically significant (P＜0.05).The number of burst pains in the observation group was less than that of the control group, and the pain stabilization time was shorter than that of the control group, the differences were statistically significant (P＜0.05). The quality of life score of the observation group after treatment was higher than that of the control group, and the difference was statistically significant (P＜0.05). The comparison of the total incidence of adverse reactions between the two groups was not statistically significant (P＞0.05). Conclusion Hydroxycodone Hydrochloride Sustained-release Tablets combined with Morphine Sulfate Sustained-release Tablets can effectively reduce the number of pain outbreaks in patients with cancer pain, significantly increase the pain relief rate and improve the quality of life of patients, and are relatively safe.

Key words： Cancer pain Hydroxycodone Hydrochloride Sustained-release Tablets Morphine Sulfate Sustained-release tablets Burst pain Pain stabilization time

引用本文:

姚辉杰. 盐酸羟考酮缓释片联合硫酸吗啡缓释片治疗中晚期癌症患者爆发痛的效果[J]. 中国当代医药, 2021, 28(28): 152-156.
YAO Hui-jie. Effect of Hydroxycodone Hydrochloride Sustained-release Tablets combined with Morphine Sulfate Sustained-release Tablets on pain outbreak in patients with advanced cancer. 中国当代医药, 2021, 28(28): 152-156.

链接本文:

http://dangdaiyiyao.com/CN/ 或 http://dangdaiyiyao.com/CN/Y2021/V28/I28/152

[1]	杨洋，吴夏慧，罗毅.盐酸羟考酮缓释片与硫酸吗啡缓释片治疗老年患者中重度癌痛的效果和安全性比较[J].中国医药，2018，13（5）：725-728.
[2]	张真.癌症爆发痛的治疗与护理干预研究进展[J].上海护理，2019，19（2）：48-52.
[3]	Peng C，Li C，Qu J，et al.Gabapentin can decrease acute pain and morphine consumption in spinal surgery patients：A meta-analysis of randomized controlled trials[J].Medicine，2017，96（15）：e6463.
[4]	车薛华，梁伟民.NCCN 成人癌性疼痛控制指南解读[J].中国医药指南，2010，8（13）：84-85.
[5]	国家卫生健康委办公厅，国家中医药局办公室.癌症疼痛诊疗规范（2018年版）[J].全科医学临床与教育，2019，17（1）：4-8.
[6]	孟歌，孙保国.世界卫生组织治疗癌症疼痛的基本规则[J].开封医专学报，1998，3：72-72.
[7]	王颖莉，陈凤娇，罗玉勤，等.中文版FACT-Leu 量表用于CML 患者生活质量评估及影响因素分析[J].成都医学院学报，2019，14（2）：234-239.
[8]	刘燕伟.盐酸羟考酮缓释片与硫酸吗啡缓释片治疗晚期恶性肿瘤重度疼痛患者的临床效果比较[J].中国民康医学，2020，32（6）：60-62.
[9]	刘考文.盐酸羟考酮缓释片与硫酸吗啡缓释片治疗重度癌痛的有效性及安全性对比[J].中国实用医药，2019，14（11）：114-116.
[10]	黄骞，张明，刘合代，等.吗啡镇痛对晚期肝癌患者血清TNF-α 及IL-6 水平影响的分析[J].标记免疫分析与临床，2019，9（6）：101-106.
[11]	李毛才.盐酸羟考酮控释片及硫酸吗啡缓释片治疗晚期恶性肿瘤重度疼痛的临床观察[J].临床医学，2020，v.40（4）：105-106.
[12]	林聪炜，林启凰，庄佳芳.2014—2016年解放军第174 医院麻醉药品的使用情况分析[J].现代药物与临床，2018，33（4）：257-261.
[13]	田银璞.探讨盐酸羟考酮控释片与硫酸吗啡缓释片对晚期癌症患者的镇痛效果[J].中国实用医药，2019，14（20）：21-22.
[14]	曹东波，宋洋，黄雷.加味芍药甘草汤联合硫酸吗啡缓释片治疗气血两虚证癌性疼痛疗效及对患者疼痛介质、炎症因子的影响[J].中国实验方剂学杂志，2018，17（24）：550-556.
[15]	Remeniuk B，King T，Sukhtankar D，et al.Disease modifying actions of interleukin-6 blockade in a rat model of bone cancer pain[J]. PAIN，2018，159（34）：225-229.
[16]	张静静，刘春香，曲卓慧，等.盐酸羟考酮控释片与硫酸吗啡缓释片对晚期癌症患者镇痛效果对比分析[J].临床医药文献电子杂志，2018，5（80）：149，152.
[17]	Mosley SA，Hicks JK，Portman DG，et al.Design and rational for the precision medicine guided treatment for cancer pain pragmatic clinical trial[J].Contemp clin trials，2018，68（41）：7-12.
[18]	周颖，向敏，王汝晋.盐酸吗啡缓释片联合普瑞巴林治疗癌性神经性疼痛的临床疗效[J].现代肿瘤医学，2019，13（7）：1200-1204.
[19]	Maindet C，Burnod A，Minello C，et al.Strategies of complementary and integrative therapies in cancer -related pain—attaining exhaustive cancer pain management [J].Support Care Cancer，2019，27（12）：37-42.
[20]	穆丽娟，王玉珮.盐酸羟考酮缓释片对晚期癌症疼痛患者镇痛效果及生活质量的影响[J].基层医学论坛，2020，24（28）：4019-4020.
[21]	刘燕伟.盐酸羟考酮缓释片与硫酸吗啡缓释片治疗晚期恶性肿瘤重度疼痛患者的临床效果比较[J].中国民康医学，2020，32（6）：60-62.
[22]	罗娟，袁琦，刁长冬，等. 盐酸羟考酮缓释片与芬太尼透皮贴剂治疗中重度癌症疼痛的不良反应比较分析[J].药物不良反应杂志，2021，23（7）：4.